Education
About Us
Working with TipRanks
Follow Us
Firebrick Pharma Limited (AU:FRE)
ASX:FRE
FRE Stock Chart & Stats
AU$0.05
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.05
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.10
Previous CloseN/A
Volume87.61K
Average Volume (3M)91.61K
Market Cap
AU$13.63M
Enterprise ValueAU$13.21M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-1.76
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,479,080
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt provides durable financial flexibility: it lowers bankruptcy risk, preserves borrowing capacity for strategic investment or commercialization, and reduces cash interest burden. Over 2–6 months this supports runway planning and gives management optionality to fund programs without immediate leverage.
Focused Anti-infectives Product StrategyA focused portfolio targeting hospital-acquired Staphylococcus aureus leverages structural healthcare demand and predictable institutional procurement. Specialization in anti-infectives creates technical and regulatory barriers to entry, enabling potentially defensible market niches and durable revenue opportunities if adoption increases.
Improving Cash Burn TrendA meaningful reduction in cash burn over recent years indicates management progress on cost control and operational efficiency. If sustained, lower burn extends runway, reduces near-term financing needs, and improves odds of reaching commercialization milestones within a multi-month horizon without immediate dilutive funding.
Bears Say
Severe Revenue DeclineA ~74% year-over-year revenue drop is a structurally significant signal of lost commercial traction or one-off contract lapses. Such steep declines erode scale economics, make fixed-cost absorption harder, and raise the bar for returning to sustainable top-line growth, increasing reliance on external funding.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow indicate the business cannot self-fund operations or expansion. Over months, continued outflows necessitate external capital, which can dilute shareholders, constrain strategic choices, and limit ability to scale commercialization or R&D without clear financing plans.
Large Persistent Losses And Weak ReturnsDeep, persistent losses and severely negative ROE reflect inability to convert revenue into sustainable profits, eroding equity value and investor confidence. Structurally, this limits reinvestment capacity, increases dilution risk if capital is raised, and implies a lengthy path to profitability absent material commercial or cost changes.
Firebrick Pharma Limited News
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.05 and its highest was AU$0.10 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Firebrick Pharma Limited’s market cap is AU$13.63M.
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Aug 27, 2026 which is in 175 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Mar 04, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 252,479,080 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.407%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Firebrick Pharma Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.66%
12-Months-Change
Fundamentals
Return on Equity
-143.50%
Trailing 12-Months
Asset Growth
-24.05%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Technical Analysis
Hexima Ltd
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Inoviq Ltd
―